Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Lineage Cell Therapeutics reports successful Q4, eyes strategic partnerships

Lineage Cell Therapeutics is advancing with promising programs like OpRegen, focusing on financial discipline and milestone achievements to drive shareholder value in 2023.
Despite net losses in 2022, Lineage's strong cash position, successful clinical outcomes, and strategic partnerships position the company for growth and leadership in cell therapy.

Lineage Cell Therapeutics reports progress in Q1 despite financial challenges

Lineage Cell Therapeutics showcased progress in OpRegen's clinical findings and financial performance in Q1 2023.
The company faces challenges in financials and market education but holds strengths in strategic partnerships and therapeutic advantages.
Opportunities lie in market positioning, collaborations, and continued innovation to drive growth and market adoption for Lineage's therapies.

Lineage Cell Therapeutics reports stable finances and advances key programs

Lineage Cell Therapeutics shows financial stability with strong cash reserves and a strategic focus on advancing key pipeline programs.
Despite challenges in patient enrollment and cell delivery, the company remains innovative and adaptable in exploring gene therapy solutions.
Positive FDA feedback on the OPC1 program and ongoing exploration of partnerships and advancements position Lineage for future growth and success.

Lineage Cell Therapeutics reports strong Q3 performance and eyes growth

Lineage Cell Therapeutics demonstrated financial stability, innovation in cell therapy, and progress in regenerative medicine programs during Q3 2023.
Challenges include study completion, safety concerns, enrollment trends, and strategic resource allocation for future growth.
Opportunities lie in market expansion, collaborations in neurology, therapeutic advancements, and regulatory success for the company.
Overall, Lineage Cell Therapeutics is positioned for growth through strategic partnerships and advancements in regenerative medicine.

Lineage Cell Therapeutics reports stable finances and program advancements

Lineage Cell Therapeutics showcased financial stability, program advancements, and strategic decisions in the Q4 2023 earnings call, emphasizing progress in OpRegen and OPC1 programs.
While facing challenges in managing expenses and uncertainties in program timelines, the company highlighted opportunities in partnerships, patient inclusion, and innovation for future growth.
Analyst questions focused on clinical outcomes, financing decisions, and program updates, reflecting investor interest in OpRegen program advancements and market potential.

Lineage Cell Therapeutics reports Q1 results, highlights partner support

Lineage Cell Therapeutics' Q1 2024 performance reflects revenue challenges but highlights strong partner support and operational preparedness.
The company faces financial losses amid investments in R&D but showcases a commitment to strategic growth and long-term success.
Challenges in revenue generation and data validation are balanced by opportunities in clinical trial efficiency, market demand, and therapeutic expansion.
Overall, Lineage's focus on innovation, partnerships, and operational readiness positions it for potential growth and success in the cell therapy space.

Lineage Cell Therapeutics extends cash runway, advances key programs

Lineage Cell Therapeutics reported financials for Q3 2024, extending cash runway and showcasing progress in key programs.
Strengths include advancements in OpRegen and ReSonance programs, with a strategic focus on manufacturing and partnerships.
Challenges lie in financial performance, maintaining cash discipline, and meeting study endpoints, while opportunities arise from collaborations and program advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company's exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc. (“Eterna”). This.

Lineage Announces Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Lineage's Chief Executive Officer, will present at Baird's 2023 Global Healthcare Conference, in a fireside chat hosted by Jack K. Allen, CFA, Senior Research Analyst, Robert W. Baird & Co. Incorporated, on September 12th, 2023 at 12:50pm ET. Baird's 2023 G.

Lineage to Present at Baird 2023 Global Healthcare Conference and H.C. Wainwright & Co. 25th Annual Global Investment Conference

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Ioana Hone - Head-Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President-Clinical & Medical Affairs Conference Call Participants Jack Allen - Baird Joe Pantginis - H. C. Wainwright Jason Bouvier - Cantor Fitzgerald Michael Okunewitch - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Second Quarter 2023 Conference Call.

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2023 Earnings Call Transcript

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics Q2 2023 Financial Results.

Lineage Cell Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 10, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, August 10, 2023, at 4:30 p.m. Eastern Time/1:30 p.

Lineage Cell Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research, today announced encouraging primary and secondary endpoint results from the recently completed clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). The Phase 1 study was a first-.

Lineage Cell Therapeutics and Cancer Research UK Report Topline Phase 1 Study Results With VAC2 for the Treatment of Advanced Non-small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June 26, 2023, according to a preliminary list of additions posted to the FTSE Russell website.

Lineage Cell Therapeutics Expected to Be Added to Russell 3000® Index

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Officer Jill Howe - Chief Financial Officer Gary Hogge - Senior Vice President of Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird Joe Joe Pantginis - H. C. Wainwright Kristen Kluska - Cantor William Wood - B.

Lineage Cell Therapeutics, Inc. (LCTX) Q1 2023 Earnings Call Transcript

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.04 per share a year ago.

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the first quarter ended March 31, 2023 and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results. “During the first quarter of this year, the Lineage team executed on multiple fronts, advancing our clinical and precli.

Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 11, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 11, 2023, at 4:30 p.m. Eastern Time/1:30 p.m. Pac.

Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes and visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation, “Exploratory optical coherence.

RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M.

Lineage to Present at 2023 AAPS National Biotechnology Conference

CarParts.com, Inc.

Solid Power

Penny stocks to buy have been the talk of the town in recent weeks as cyclical assets have started to make a comeback this year. Penny stocks tend to perform poorly during market downturns.

3 Penny Stocks to Buy During Market Downturns

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc.

Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from a Phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute.

RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Ioana Hone - Head of IR Brian Culley - CEO Jill Howe - Chief Financial Officer Gary Hogge - SVP, Clinical and Medical Affairs Conference Call Participants Jack Allen - Baird William Wood - B. Riley Securities Kristen Kluska - Cantor Fitzgerald Joe Pantginis - HC Wainwright Joanne Lee - Maxim Group Operator Welcome to the Lineage Cell Therapeutics Fourth Quarter and Full Year 2022 Conference Call.

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2022 Earnings Call Transcript

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 35.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q4 Loss, Misses Revenue Estimates

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that results from imaging analyses of structural changes in addition to visual data from a Phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023).

RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2022 financial and operating results on Thursday, March 9, 2023, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 9, 2023, at 4:30 p.m.

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to replace and restore specific cell types of the human body, today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc.

Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications

Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss

CARLSBAD, Calif.--( BUSINESS WIRE )--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive Officer, will present at the BTIG Virtual Ophthalmology Day, on November 29, 2022 at 12:00pm Eastern Time, in a fireside chat hosted by Yun Zhong, Ph.D., Director, Biotech Equity Research at BTIG. Mr. Culley will also be presenting at Cantor Fitzgerald's Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference on December 8, 2022 at 1:45pm Eastern as part of the “Ophthalmology Panel, Vision For The Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories To Shake Things Up”. The panel will be hosted by Jennifer Kim, Vice President, Equity Research at Cantor Fitzgerald, and the conference is taking place at the Fontainebleau Miami Beach hotel, December 7-8, 2022.

Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference

CARLSBAD, Calif.--( BUSINESS WIRE )--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that its partner Genentech, a member of the Roche Group, has launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 (OpRegen), a retinal pigment epithelial cell therapy. The study is intended to optimize subretinal surgical delivery and evaluate the safety and activity of OpRegen in approximately 30, and up to 60 patients with geographic atrophy (GA) secondary to age-related macular degeneration. The primary objectives of the study are to evaluate (i) the proportion of patients with subretinal surgical delivery of OpRegen to target regions under the retina, and (ii) to evaluate the safety of subretinal surgical delivery of OpRegen as measured by the incidence and severity of procedure-related adverse events at 3 months following surgery. A key secondary objective is to evaluate the proportion of patients with qualitative improvement in retinal structure, as determined by Optical Coherence Tomography (SD-OCT) imaging, within 3 months following surgery. RG6501 (OpRegen) is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech.

Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

News for Lineage Cell Therapeutics Inc Stock (LCTX)